Latest Sionna Therapeutics News & Updates

See the latest news and media coverage for Sionna. We track all announcements, press releases, and industry mentions in real time, all in one place.

Sionna Therapeutics (Sionna)

Biopharmaceutical company developing novel cystic fibrosis therapies

sionnatx.com

Headquarters: Boston, United States
Founded year: 2019
Company type: Public company
Number of employees: 70–200
Industry: Pharmaceuticals

Last updated Today

Latest news about Sionna Therapeutics (Sionna)

In short: Sionna experienced a sharp share decline following trial failures after previously securing $182 million to advance its CF pipeline.

Company announcements

August 10 Sionna

Sionna reported topline data from two cystic fibrosis trials

The trials evaluated NBD1 stabilizers as a potential treatment for cystic fibrosis, with full results available in a press release.

August 6 Sionna

Sionna reported Q2 2026 financial results and business updates.

The company's cash of $268.3 million is expected to fund operations into 2028, while Phase 2a and Phase 1 trials remain on track for summer data readouts.

July 31 Sionna

Sionna learns from CF community to advance new options

The company partners with advocacy groups, healthcare professionals, caregivers, and patients to understand real-world needs. Its insights inform work on new CF treatment options.

July 10 Sionna

Sionna presented its cystic fibrosis pipeline at healthcare conferences.

Sionna discussed its cystic fibrosis pipeline at the Goldman Sachs and Jefferies global healthcare conferences. Replays of the presentations are available.

Media coverage

Yesterday Yahoo Finance

One Company's Clinical Miss Is Another's Moat: Vertex Rallies as Sionna's CF Bet Collapses

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or...

Yesterday TechStock²

Sionna Stock Falls 91% as Failed CF Trial Pushes Valuation Below Cash

Sionna Therapeutics NASDAQ:SION closed 91.2% lower on Monday after its lead clinical readout failed.

Yesterday Qz

Qz

Sionna Therapeutics reported Monday that its experimental cystic fibrosis drug SION-719 failed to meet the key activity endpoint in a mid-stage trial, sending the company's...

August 10 TechStock²

Sionna Therapeutics (NASDAQ:SION) Drops 92% After Failed Study, Shares Fall Below Gross Cash

Sionna Therapeutics (NASDAQ:SION) Drops 92% After Failed Study, Shares Fall Below Gross Cash - TechStock²...

Never miss news about Sionna

Track Sionna and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Sionna competitors & trending companies

Browse news for competitors to Sionna and other trending companies.